relaxant: Small Doses Muscle Relaxant in General Anesthesia

Sponsor
Mansoura University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04344262
Collaborator
(none)
60
1
2
32.3
1.9

Study Details

Study Description

Brief Summary

This study will be held to assess the effect of minimal dose muscle relaxant on postoperative pulmonary function. The time to extubation in minutes will be the primary outcome as a clinical indicator of the return of muscle power. The extubation time will be defined as the time from injecting the muscle relaxant reversing agent given when regain the train of four (TOF) ratio to 0.9 till removal of endotracheal tube.

Intraoperative surgical conditions will be assessed in the form of surgeon satisfaction and the need for more muscle relaxant boluses. Postoperative complications as desaturation (peripheral oxygen saturation (Spo2) less than 90%), the need for re-intubation or ventilation support will be recorded. Patient lung will be assessed using ultrasound-based lung aeration score. Also, the diaphragmatic and intercostal muscle function will be assessed in the early postoperative period. Immediate postoperative pulmonary function tests will be evaluated using simple spirometer. Patients will be followed up for 28 days for detection of pulmonary complications.

Condition or Disease Intervention/Treatment Phase
  • Drug: Atracurium Besylate regular dose
  • Drug: Atracurium Besylate minial dose
N/A

Detailed Description

After arrival to the operating theater, a thoracic US examination will be done using LUS dynamic re-aeration score. Patients will be randomly allocated via sealed opaque envelopes into 2 groups of 30 patients each; control (C) group and minimal dose (Min) group.

For general anesthesia; intubating dose of muscle relaxant will be injected according to the study group; in C group; atracurium 0.5 mg/kg while in min group 0.2 mg/kg will be injected. The trial for intubation will be assessed and recorded. Train-of-four (TOF) stimulation will be maintained less than 2 throughout the intraoperative period in the control group. While, in the min group, boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomly allocated via sealed opaque envelopes into 2 groups of 30 patients each; control (C) group and minimal dose (M) groupPatients will be randomly allocated via sealed opaque envelopes into 2 groups of 30 patients each; control (C) group and minimal dose (M) group
Masking:
Double (Participant, Investigator)
Masking Description:
Basal US assessment and its repetition in the recovery room, will be done by an anesthetist who is not involved in randomization or anesthetic technique except, after ending the surgery and after dressing, he will be responsible for reversal agent injection and the extubation with recording the extubation time
Primary Purpose:
Treatment
Official Title:
Respiratory Benefits of Small Doses Muscle Relaxant in General Anesthesia
Actual Study Start Date :
Apr 22, 2020
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: control (C) group

Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg Maintenance doses of muscle relaxant will be given throughout the intraoperative period to maintain the Train-of-four values continuously less than 2

Drug: Atracurium Besylate regular dose
Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg Maintenance doses of muscle relaxant will be given throughout the intraoperative period to maintain the Train-of-four values continuously less than 2

Experimental: minimal dose (M) group

Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal.

Drug: Atracurium Besylate minial dose
atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal

Outcome Measures

Primary Outcome Measures

  1. The time to extubation in minutes [after injecting the muscle relaxant till removal of the tracheal tube]

    the time from injecting the muscle relaxant reversing agent given when regain the train of four (TOF) ratio to 0.9 till removal of endotracheal tube

Secondary Outcome Measures

  1. Time to the first intraoperative need of muscle relaxant bolus (Atracurium), in the M group [Given intraoperatively only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg]

    blouse of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg

  2. Total doses of propofol used in M group post-induction [intraoperatively]

    a bolus dose of propofol 0.5 mg/kg given in the M group, upon complain of the surgeon and before boluses of muscle relaxant

  3. first Postoperative day complications [after removal of the tracheal tube and for 24 hours postoperative]

    desaturation (Spo2 less than 90%), need for re-intubation, need of ventilation support

  4. lung aeration via Lung ultrasound dynamic re-aeration score [basal immmediate preoperative & with first 30 minutes postoperative]

    0= normal aeration (horizontal A-lines or ≤ 2 B-lines); 1 = moderate loss of aeration (multiple B-lines, either regularly spaced (7 mm apart), or irregularly spaced and even coalescent but only visible in a limited area of the intercostal space); 2 = loss of aeration (multiple coalescent B-lines, in prevalent areas of the intercostal spaces and observed in one or several intercostal spaces); 3 = complete loss of aeration (lung consolidation, with or without air bronchograms)

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • adult patients

  • aged from 20 to 50 years old

  • scheduled for non-cardiothoracic surgery

  • under general anesthesia

  • in supine position

  • after informed consent

Exclusion Criteria:
  • American Society of Anesthesiologists (ASA) score more than 3

  • suspected full stomach or who will undergo intervention expected to necessitate profound muscle relaxation or dressing interferes with ultrasound (US) probe positioning

  • Lung parenchymatous disease

  • renal disease

  • hepatic disease

  • neuromuscular disease

  • electrolytes imbalanc

  • on medication interfere with muscle contraction

  • with known allergy to any drug used in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mansoura University-Emergency hospital-ICU Mansoura Egypt

Sponsors and Collaborators

  • Mansoura University

Investigators

  • Study Director: Maha Ahmed Abozeid, MD, Faculty of Medicine - Mansoura University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
maha abou-zeid, Lecturer of anesthesia and surgical intensive care, Mansoura University
ClinicalTrials.gov Identifier:
NCT04344262
Other Study ID Numbers:
  • respiratory effect
First Posted:
Apr 14, 2020
Last Update Posted:
Mar 23, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 23, 2022